NQF:  

The Steering Committee began meeting in August 2011 to evaluate the submissions and prepare the draft report.

Measures to be reviewed 

Anemia
0252: Assessment of Iron Stores
1660: ESRD Patients Receiving Dialysis: Hemoglobin Level <10g/dL
1666: Patients on Erythropoiesis Stimulating Agent (ESA)--Hemoglobin Level > 12.0 g/dL
1667: (Pediatric) ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL (REVISED)

Cardiovascular
0626: Chronic Kidney Disease - Lipid Profile Monitoring (REVISED)
0627: Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent (REVISED)
1633: Blood Pressure Management (REVISED)
1662: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy (REVISED)
1668: Laboratory Testing (Lipid Profile) (REVISED)

Dialysis Adequacy (HD)
0247: Hemodialysis Adequacy Clinical Performance Measure I: Hemodialysis Adequacy- Monthly measurement of delivered dose
0248: Hemodialysis Adequacy Clinical Performance Measure II: Method of Measurement of Delivered Hemodialysis Dose
0249: Hemodialysis Adequacy Clinical Performance Measure III: Hemodialysis Adequacy--HD Adequacy-- Minimum Delivered Hemodialysis Dose (REVISED)
0250: ESRD- HD Adequacy CPM III: Minimum Delivered Hemodialysis Dose for ESRD hemodialysis patients undergoing dialytic treatment for a period of 90 days or greater.
0323: Hemodialysis Adequacy: Solute (REVISED)

Dialysis Adequacy (PD)
0253: Peritoneal Dialysis Adequacy Clinical Performance Measure I - Measurement of Total Solute Clearance at Regular Intervals
0254: Peritoneal Dialysis Adequacy Clinical Performance Measure II - Calculate Weekly KT/Vurea in the Standard Way
0318: Peritoneal Dialysis Adequacy Clinical Performance Measure III - Delivered Dose of Peritoneal Dialysis Above Minimum (REVISED)
0321: Peritoneal Dialysis Adequacy: Solute (REVISED)

Mineral Metabolism
0255: Measurement of Serum Phosphorus Concentration (REVISED)
0261: Measurement of Serum Calcium Concentration
0570: CHRONIC KIDNEY DISEASE (CKD): MONITORING PHOSPHORUS (REVSIED)
0571: CHRONIC KIDNEY DISEASE (CKD): MONITORING PARATHYROID HORMONE (PTH)
0574: CHRONIC KIDNEY DISEASE (CKD): MONITORING CALCIUM
1655: ESRD patients with PTH 400pg/mL and not treated with a calcimimetic or vitamin D analog.
1658: ESRD patients with PTH 130pg/mL and continued treatment with a calcimimetic or vitamin D analog.

Mortality
0369: Dialysis Facility Risk-adjusted Standardized Mortality Ratio (32) Level (REVISED)

Patient Education
0320: Patient Education Awareness—Physician Level
0324: Patient Education Awareness—Facility Level

Vascular Access
0251: Vascular Access—Functional AVF or Evaluation by Vascular Surgeon for Placement (REVISED)
0256: Hemodialysis Vascular Access- Minimizing use of catheters as Chronic Dialysis Access (REVISED)
0257: Hemodialysis Vascular Access- Maximizing Placement of Arterial Venous Fistula (AVF) (REVISED)
0259: Hemodialysis Vascular Access - Decision-making by Surgeon to Maximize Placement of Autogenous Arterial Venous Fistula (REVISED)
0262: Vascular Access—Catheter Vascular Access and Evaluation by Vascular Surgeon for Permanent Access